Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation

“…A recent SR/MA of RCTs (2010–2020) on AOM and mortality (all-cause and cardiovascular) and cardiovascular events (myocardial infarction, stroke, heart failure) identified 28 RCTs comparing one AOM (orlistat, NB, phentermine/topiramate, liraglutide and lorcaserin) to placebo. 112 Pooling all RCTs together showed no significant reduction in overall mortality, cardiovascular mortality nor cardiovascular outcomes, with the use of AOM compared to placebo. 112 Interestingly, the meta-regression showed that total body weight loss was inversely associated with mortality risk.…”

“… 112 Pooling all RCTs together showed no significant reduction in overall mortality, cardiovascular mortality nor cardiovascular outcomes, with the use of AOM compared to placebo. 112 Interestingly, the meta-regression showed that total body weight loss was inversely associated with mortality risk. 112 …”

“… 112 Interestingly, the meta-regression showed that total body weight loss was inversely associated with mortality risk. 112 …”

Body Mass Index, Obesity, and Mortality—Part II

“…This is substantially greater than the 15%-to-18% reductions in mortality with intentional weight loss through lifestyle interventions 8,10 . Studies with weight loss drugs have not shown significant risk reductions in mortality compared with placebo, although results from these studies indicate weight loss is associated with a lower mortality rate 32 . Considering that pharmacotherapies and intensive lifestyle interventions have generally resulted in 5% to 12% body weight reductions, 32 compared with 20% to 30% with bariatric surgery, 30,31 it is possible that the more substantial weight loss will be associated with a reduced risk of mortality.…”

“…8,10 Studies with weight loss drugs have not shown significant risk reductions in mortality compared with placebo, although results from these studies indicate weight loss is associated with a lower mortality rate. 32 Considering that pharmacotherapies and intensive lifestyle interventions have generally resulted in 5% to 12% body weight reductions, 32 compared with 20% to 30% with bariatric surgery, 30,31 it is possible that the more substantial weight loss will be associated with a reduced risk of mortality. In addition, the maintenance of weight loss may be important for mortality, because most individuals with obesity using lifestyle interventions to lose weight tend to regain much or all of lost weight, whereas many bariatric surgery patients experience comparatively little weight regain with time.…”